Samuels - Lab

We aim to shed new light on the complex networks formed in #melanoma, and learn how we can utilize this information to treat melanoma patients
@WeizmannScience

[Samuels - Lab @Samuels_lab]

Thank you @Nofar74793338!

[Samuels - Lab @Samuels_lab]

Here at the Samuels lab we believe in safety first!
#Lentivirus #SafetyFirst #LabLife

[Samuels - Lab @Samuels_lab]

Proud of @samuels_yardena for her fascinating plenary session at the @AACR annual meeting in Chicago! A great thank you to the program committee chairs, Drs. Matthew G. Vander Heiden and Lillian L. Siu for this amazing opportunity.
@mvh_lab @lillian_siu #AACR25 #AACR2025

[ACIR @ACIR_org]

Translation dysregulation may serve as a new source for identifying cancer-associated antigens, and may also help to predict responses to checkpoint blockade https://t.co/MX3yfxi2HU  @chen_weller  @samuels_yardena @Samuels_lab #CheckpointBlockade #CancerImmunotherapy

[Chen Weller @chen_weller]

Thrilled to share our work in Cancer Cell! Huge thanks to my PI and mentor @samuels_yardena ,OsnatBartok, and our collaborators @chrismcginnis,@Satpathology , Andreas Schlosser,@EytanRuppin & more. We reveal how impaired translation fidelity enhances anti-tumor immunity!🧵(1/8)

[Weizmann Institute @WeizmannScience]

In a study published in @Cancer_Cell, researchers from @Samuels_lab manipulated cancer cells into making themselves visible to the immune system, creating a new approach that gives hope to patients with previously untreatable disease>>https://t.co/V90RKJ6U9M @samuels_yardena

[OncoDaily @oncodaily]

AACR - The Various Layers of Intratumor Heterogeneity and Their Impact on Tumor Immunity
@AACR @samuels_yardena

https://t.co/wJEHfddGg5

#Cancer #CancerResearch #AACR #MedX #MedNews #MedEd #IntratumorHeterogeneity #Medicine #Health #Oncology #OncoDaily

[AACR @AACR]

The Various Layers of Intratumor Heterogeneity and Their Impact on Tumor Immunity:
Yardena Samuels will address this topic in a plenary session on Targeting the Cancer Ecosystem (Tuesday, April 29) at #AACR25. Learn more:
https://t.co/DKaZw1uxwc
@samuels_yardena

[Samuels - Lab @Samuels_lab]

8/8 All this would not be possible without the hard work of Sapir Cohen Shvefel, @joyp_ai @sathpathology @NCIEytanRuppin, @samuels_yardena and colleagues.
@weizmannScience
#CancerResearch #Immunotherapy

[Samuels - Lab @Samuels_lab]

Our new paper on Macrophage Migration Inhibitory Factor (MIF) as a key regulator of immune evasion in melanoma, is now published in @CD_AACR (full study here:https://t.co/8JiVP0buDq)
Step-by-step breakdown of this exciting research follows:

[Samuels - Lab @Samuels_lab]

7/8 Our findings suggest that MIF expression is an important determinant of aggressive tumor growth in low-ITH tumors in melanoma and could lead to new strategies for treating patients with homogeneous, high-MIF-expressing tumors that don't respond to immune checkpoint therapy.

[Weizmann Institute @WeizmannScience]

New study in @Samuels_lab, published in Cancer Discovery, reveals a key player in the development of aggressive melanoma tumors: a small immune system protein called Mif. Findings promise to open new directions of therapy >> https://t.co/XP2bgKh1Xm
@samuels_yardena

[Samuels - Lab @Samuels_lab]

Congratulations to our very own Sapir Cohen Shvefel! Her paper on Macrophage Migration Inhibitory Factor (MIF) as a key regulator of immune evasion in #melanoma, is now published in @CD_AACR ! Full article here: https://t.co/8JiVP0buDq

[yardena samuels @samuels_yardena]

Thrilled to share that our new paper on Macrophage Migration Inhibitory Factor (MIF) as a key regulator of immune evasion in melanoma, is now published in @Cancer Discovery! Find the full study here: https://t.co/Gl88qcQ7fy